ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2024
An improved protocol for bacteria identification by MALDI-TOF MS directly from positive blood cultures.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Comparative analytical performance of Autof MS2600 and Biotyper Sirius for rapid MALDI-TOF MS identification of microorganisms from positive blood cultures.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Rapid identification directly from urine using QUICKprep kit.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Article
- Five things the intensivist cannot forget in the management of invasive candidiasis.Critical care science · 2026Article
- Rapid identification and antimicrobial susceptibility testing of pathogenic microorganisms from positive blood cultures.PloS one · 2026Article
- Plug-and-Play Centrifuge-Only Device for Rapid Sepsis Diagnosis.Advanced healthcare materials · 2025Article
- Isolation and identification of bacteria from blood within 12 h using standard laboratory equipment.Scientific reports · 2025Article
- Rapid and cost-effective identification of microorganisms from positive blood cultures using MALDI-TOF MS.BMC infectious diseases · 2025Article
- Clinical evaluation of an in-house Xpert Lysate-based Method combined with MALDI-TOF MS for the rapid identification of positive blood cultures.BMC microbiology · 2025Article
- Phenotypic Ultra-Rapid Antimicrobial Susceptibility Testing for Ceftazidime-Avibactam: In Support of Antimicrobial Stewardship.Microorganisms · 2025Article
- Rapid Determination of Colistin Susceptibility by Flow Cytometry Directly from Positive Urine Samples-Preliminary Results.International journal of molecular sciences · 2025Article
- Rapid Phenotypic and Genotypic Antimicrobial Susceptibility Testing Approaches for Use in the Clinical Laboratory.Antibiotics (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
FASTinov® developed a rapid antimicrobial susceptibility test that includes the purification of a bacterial suspension directly from positive blood cultures (BC). In order to streamline laboratory workflow, the use of the bacterial suspension obtained through FASTinov® sample prep was tested for identification (ID) by matrix absorption laser deionization-time of flight mass spectrometry (MALDI-TOF MS) (Bruker) in 364 positive BC, and its accuracy assessed comparing with the MALDI-TOF MS ID of the next-day subcultured colonies. FASTinov sample prep was highly reliable for rapid ID directly from BC with proportion of agreement of 94.9% for Gram-positive and 96.3% for Gram-negative bacteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.